Zacks Investment Research upgraded shares of AC Immune (NASDAQ:ACIU) from a hold rating to a buy rating in a research report released on Tuesday morning. They currently have $5.75 target price on the stock.

According to Zacks, “AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. “

Several other brokerages also recently weighed in on ACIU. UBS Group started coverage on shares of AC Immune in a report on Friday, January 4th. They issued a buy rating and a $16.00 target price for the company. BidaskClub downgraded shares of AC Immune from a strong-buy rating to a buy rating in a report on Tuesday, February 5th. HC Wainwright reaffirmed a buy rating and issued a $18.00 target price on shares of AC Immune in a report on Thursday, January 24th. Finally, ValuEngine downgraded shares of AC Immune from a hold rating to a sell rating in a report on Monday. One research analyst has rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of Buy and an average target price of $12.35.

Shares of ACIU stock opened at $4.84 on Tuesday. AC Immune has a 1 year low of $3.25 and a 1 year high of $17.40.

AC Immune (NASDAQ:ACIU) last issued its earnings results on Thursday, March 21st. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of $0.55 by ($0.77). The firm had revenue of $1.41 million during the quarter, compared to the consensus estimate of $56.97 million. AC Immune had a negative return on equity of 33.97% and a negative net margin of 706.11%. Sell-side analysts forecast that AC Immune will post 0.34 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the business. Barclays PLC lifted its stake in AC Immune by 726.2% in the 4th quarter. Barclays PLC now owns 6,378 shares of the company’s stock worth $61,000 after purchasing an additional 5,606 shares in the last quarter. Marshall Wace LLP purchased a new stake in AC Immune in the 3rd quarter worth $107,000. GSA Capital Partners LLP purchased a new stake in AC Immune in the 3rd quarter worth $110,000. Squarepoint Ops LLC purchased a new stake in AC Immune in the 4th quarter worth $121,000. Finally, JPMorgan Chase & Co. purchased a new stake in AC Immune in the 3rd quarter worth $142,000. Institutional investors and hedge funds own 30.74% of the company’s stock.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

See Also: Conference Calls and Individual Investors

Get a free copy of the Zacks research report on AC Immune (ACIU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.